Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
Profitability
This table compares Entrada Therapeutics and X4 Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -3,537.73% | -57.61% | -46.54% |
| X4 Pharmaceuticals | -568.80% | -63.05% | -36.89% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Entrada Therapeutics and X4 Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| X4 Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
Entrada Therapeutics currently has a consensus target price of $17.75, indicating a potential upside of 270.56%. X4 Pharmaceuticals has a consensus target price of $11.25, indicating a potential upside of 311.33%. Given X4 Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Entrada Therapeutics.
Valuation & Earnings
This table compares Entrada Therapeutics and X4 Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entrada Therapeutics | $4.69 million | 39.80 | -$143.75 million | ($3.96) | -1.21 |
| X4 Pharmaceuticals | $35.11 million | 7.72 | -$79.20 million | ($1.20) | -2.28 |
X4 Pharmaceuticals has higher revenue and earnings than Entrada Therapeutics. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Entrada Therapeutics has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
Summary
X4 Pharmaceuticals beats Entrada Therapeutics on 8 of the 13 factors compared between the two stocks.
About Entrada Therapeutics
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
